Clinical Utility of the Platelet Function Analyzer (PFA-100) for the Assessment of the Platelet Status in Patients with Congestive Heart Failure (EPCOT trial)

Serebruany, Victor L.; Alford, Amanda B.; Meister, Andrew F.; Fuzaylov, Sergey Y.; Gattis, Wendy A.; Gurbel, Paul A.; O’Connor, Christopher M.

doi:10.1016/s0049-3848(00)00431-x

Cited by 13 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the fact the several studies have sought to use the CT in a prospective manner to diagnose platelet function abnormalities that could lead to thrombosis in humans, test results are highly variable and therefore limited in their ability to consistently correlate with severity of disease or to predict future cardiac events 28–30 . We were unable to identify shorter CTs in cats with HCM.…”

Section: Resultsmentioning

confidence: 93%

Platelet function in clinically healthy cats and cats with hypertrophic cardiomyopathy: analysis using the Platelet Function Analyzer‐100

Jandrey¹,

Norris

MacDonald

et al. 2008

Veterinary Clinical Pathol

View full text Add to dashboard Cite

Background: There is currently no simple analytical tool for the evaluation of hypercoagulability in cats. The Platelet Function Analyzer-100 s (PFA-100; Dade Behring Inc., Deerfield, IL, USA) is a bench-top machine that evaluates platelet function by measuring closure time (CT) in citrated whole blood under high shear conditions. We hypothesized that cats with hypertrophic cardiomyopathy (HCM) have up-regulated platelet function, which shortens their CT and increases their risk for thromboembolic events. Objectives: The goals of this study were to: (1) establish a feline reference interval for CT using the PFA-100, (2) measure CT in blood from cats with HCM, and (3) determine if there is a measurable difference between the CT of healthy cats compared with cats with HCM. Methods: Citrated blood samples from 42 clinically healthy cats and 30 cats with HCM were analyzed according to manufacturer's specifications. CT was measured in triplicate and the mean value was used for analysis. Transformed data were compared between clinically healthy cats and cats with HCM using a Student's t-test, and among cats with mild, moderate, or severe HCM using ANOVA. Results: The median CT of clinically healthy cats was 64 seconds (range 43-176 seconds). The median CT of cats with HCM was 74 seconds (range 48-197 seconds). There was no significant difference in CT between cats with HCM and clinically healthy cats. There also were no significant differences in cats with mild, moderate, or severe HCM. Conclusions: A feline reference interval for PFA-100 CT will be useful in future studies of platelet function in cats. Cats with HCM do not have shorter CTs when compared with clinically healthy cats.

show abstract

Section: Resultsmentioning

confidence: 93%

Platelet function in clinically healthy cats and cats with hypertrophic cardiomyopathy: analysis using the Platelet Function Analyzer‐100

Jandrey¹,

Norris

MacDonald

et al. 2008

Veterinary Clinical Pathol

View full text Add to dashboard Cite

show abstract

“…In this study the platelet function was evaluated using optical aggregometry, flow cytometry and PFA-100 method (aspirin nonresponsiveness was identified when 4 of the following 5 parameters occurred: collagen-induced aggregation > 70%; adenosine diphosphate-induced aggregation > 60%; whole blood aggregation > 18 ohms; expression of active GP IIb-IIIa > 220 log mean flurorescence intensity units; and P-Selectin positivity > 8%). However there is substantial interindividual variability of platelets characteristics in patients with heart failure and PFA-100 method is not a particularly useful device for screening patients with congestive heart failure and monitoring the aspirin use [72].…”

Section: Aspirin Resistance and Heart Failurementioning

confidence: 99%

Aspirin Resistance: Definitions, Mechanisms, Prevalence, and Clinical Significance

Macchi

Sorel²,

Christiaens³

2006

curr pharm des

View full text Add to dashboard Cite

Aspirin is the most commonly used therapeutic agent in prevention of vascular ischemic events. Aspirin exerts its antithrombotic effect primarily by interfering with the biosynthesis of thromboxane A2 (TXA2) and inhibition of TXA2 -dependent platelet aggregation. A meta-analysis of secondary prevention trials indicated that aspirin reduced major cardiovascular or cerebral events by 25%. This led to the widespread use of aspirin for prevention of cardiovascular events. However, it appears that aspirin antiplatelet effect is not uniform in all patients and previous studies estimated that 8-45% of the population were aspirin resistant. Furthermore, (i) the optimal dosage of aspirin for complete inhibition of platelet aggregation by physiological agonists (i.e arachidonic acid) is subject to great interindividual variability, (ii) the tests to detect aspirin resistance in vitro are subject to debate and (iii) the mechanisms by which some patients are resistant to aspirin in vitro remain to be determined. Despite these unresolved questions, recent clinical studies provide the reliable evidence that aspirin resistance correlates with confirmed clinical unresponsiveness, highlighting the clinical interest of determining the aspirin inhibitory effects on patients' platelets. In conclusion, discovery of aspirin resistance in individuals might be important in order to devise better anti-platelet strategies and improve our ability to prevent acute thrombotic complication.

show abstract

“…Several studies have been performed with the PFA-100, and have shown that effect of aspirin treatment on platelet function can be measured with this system [16,17]. In previous reports, aspirin non-responsiveness has been described as having a normal closure time by PFA-100 assay despite confirmed treatment with aspirin.…”

Section: Pfa-100 Assaymentioning

confidence: 99%

“…The platelet function analyzer (PFA)-100 (DadeBehring) is a simple, quantitative, whole-blood automatic platelet function assay, which simulates platelet based hemostasis in vitro [14,15]. It is suggested that the PFA-100 may be used to screen the aspirin responder or nonresponder status of patients taking aspirin [16,17]. Aspirin non-responsiveness has been described as having a normal closure time (CT) by PFA-100 assay despite confirmed treatment with aspirin [6,9,11].…”

Section: Introductionmentioning

confidence: 99%

A new definition of aspirin non-responsiveness by Platelet Function Analyzer-100™ and its predictors

et al. 2006

View full text Add to dashboard Cite

show abstract

Clinical Utility of the Platelet Function Analyzer (PFA-100) for the Assessment of the Platelet Status in Patients with Congestive Heart Failure (EPCOT trial)

Cited by 13 publications

References 22 publications

Platelet function in clinically healthy cats and cats with hypertrophic cardiomyopathy: analysis using the Platelet Function Analyzer‐100

Platelet function in clinically healthy cats and cats with hypertrophic cardiomyopathy: analysis using the Platelet Function Analyzer‐100

Aspirin Resistance: Definitions, Mechanisms, Prevalence, and Clinical Significance

A new definition of aspirin non-responsiveness by Platelet Function Analyzer-100™ and its predictors

Contact Info

Product

Resources

About